Hanmi Pharm Co Ltd (KO:128940) — Market Cap & Net Worth
Market Cap & Net Worth: Hanmi Pharm Co Ltd (128940)
Hanmi Pharm Co Ltd (KO:128940) has a market capitalization of $3.95 Billion (₩5.83 Trillion) as of May 2, 2026. Listed on the KO stock exchange, this Korea-based company holds position #4184 globally and #110 in its home market, demonstrating a -6.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hanmi Pharm Co Ltd's stock price ₩460000.00 by its total outstanding shares 12680214 (12.68 Million). Analyse Hanmi Pharm Co Ltd cash flow conversion to see how efficiently the company converts income to cash.
Hanmi Pharm Co Ltd Market Cap History: 2015 to 2026
Hanmi Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $5.03 Billion to $3.95 Billion (4.16% CAGR).
Hanmi Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hanmi Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Hanmi Pharm Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Hanmi Pharm Co Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.03 Billion | $1.32 Trillion | $154.44 Billion | 0.00x | 0.03x |
| 2016 | $2.11 Billion | $882.72 Billion | $23.33 Billion | 0.00x | 0.09x |
| 2017 | $4.41 Billion | $916.59 Billion | $60.43 Billion | 0.00x | 0.07x |
| 2018 | $3.58 Billion | $1.02 Trillion | $24.89 Billion | 0.00x | 0.14x |
| 2019 | $2.34 Billion | $1.11 Trillion | $52.11 Billion | 0.00x | 0.04x |
| 2020 | $2.95 Billion | $1.08 Trillion | $11.96 Billion | 0.00x | 0.25x |
| 2021 | $2.27 Billion | $1.20 Trillion | $67.03 Billion | 0.00x | 0.03x |
| 2022 | $2.50 Billion | $1.33 Trillion | $82.79 Billion | 0.00x | 0.03x |
| 2023 | $3.03 Billion | $1.49 Trillion | $146.23 Billion | 0.00x | 0.02x |
| 2024 | $2.41 Billion | $1.50 Trillion | $121.32 Billion | 0.00x | 0.02x |
Competitor Companies of 128940 by Market Capitalization
Companies near Hanmi Pharm Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Hanmi Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Hanmi Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hanmi Pharm Co Ltd's market cap moved from $5.03 Billion to $ 3.95 Billion, with a yearly change of 4.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩3.95 Billion | +1.77% |
| 2025 | ₩3.88 Billion | +61.14% |
| 2024 | ₩2.41 Billion | -20.35% |
| 2023 | ₩3.03 Billion | +20.83% |
| 2022 | ₩2.50 Billion | +10.31% |
| 2021 | ₩2.27 Billion | -23.05% |
| 2020 | ₩2.95 Billion | +26.28% |
| 2019 | ₩2.34 Billion | -34.71% |
| 2018 | ₩3.58 Billion | -18.87% |
| 2017 | ₩4.41 Billion | +108.82% |
| 2016 | ₩2.11 Billion | -58.04% |
| 2015 | ₩5.03 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Hanmi Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.95 Billion USD |
| MoneyControl | $3.95 Billion USD |
| MarketWatch | $3.95 Billion USD |
| marketcap.company | $3.95 Billion USD |
| Reuters | $3.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more